fda glp-1 warning letters september 2025 news Issues to Telehealth Companies for False Clai FDA unleashes warning letters to

In 2026, the number of people with no commercial insurance coverage for Wegovy increased by 42 percent compared to 2025

Wilbon SS, Kolonin MG

The pattern repeats with each subsequent dose increase: a brief period of adjustment followed by adaptation

Gallbladder disease cholelithiasis and cholecystitis have been reported, associated with the drug and with rapid weight loss

Trial Status: Recruiting Clinical Trials Identifier: NCT06797869 Trial Name: A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy Diabetes Type: Type 2 diabetes Trial Sponsor: Novo Nordisk A/S Why is this study important